Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis (OPTION)

This study has been completed.
Sponsor:
Information provided by:
ESM Technologies, LLC
ClinicalTrials.gov Identifier:
NCT00750477
First received: September 8, 2008
Last updated: April 24, 2009
Last verified: April 2009
  Purpose

The purpose of this study is to evaluate the effectiveness of Natural Eggshell Membrane (NEM) for the relief of pain and stiffness associated with moderate osteoarthritis of the knee and to compare the effectiveness of NEM to placebo.


Condition Intervention
Osteoarthritis
Dietary Supplement: Natural Eggshell Membrane
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness and Safety of Natural Eggshell Membrane (NEM) in the Treatment of Pain & Stiffness Associated With Moderate Osteoarthritis of the Knee

Resource links provided by NLM:


Further study details as provided by ESM Technologies, LLC:

Primary Outcome Measures:
  • The primary endpoint of the study was measurement of the effectiveness of NEM® in relieving pain, stiffness, and discomfort associated with moderate OA of the knee and to compare its effectiveness to placebo. [ Time Frame: 10, 30, & 60 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary objectives of the study were to evaluate tolerability and any adverse reactions associated with supplementation with NEM®. [ Time Frame: 10, 30, & 60 Days ] [ Designated as safety issue: Yes ]

Enrollment: 67
Study Start Date: December 2004
Study Completion Date: May 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NEM Treatment
Oral NEM® 500 mg, once daily.
Dietary Supplement: Natural Eggshell Membrane
oral NEM® 500 mg, taken once daily for eight weeks.
Other Name: NEM
Placebo Comparator: Placebo Dietary Supplement: Placebo
Placebo comparator containing inactives.

Detailed Description:

Osteoarthritis (OA) is the most prevalent form of arthritis and is estimated to affect nearly 27 million adults in the U.S., with one third of those 65 and older having been diagnosed with OA. As the population ages, this estimate is expected to grow rapidly. Traditional treatments for OA primarily attempt to address the symptoms (pain, inflammation, and discomfort) associated with the disease. This usually involves the use of analgesics (i.e. acetaminophen, tramadol), non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. ibuprofen, diclofenac), or cyclooxygenase-2-specific (COX-2) NSAIDs (i.e. celecoxib) alone or in combination. Steroid and hyaluronic acid injections have also been used with some success. Many of these treatments have shown limited effectiveness in randomized controlled clinical trials (RCTs). To avoid the cardiac risks and gastrointestinal issues associated with traditional OA treatments (particularly with long-term use), many patients have turned to complementary and alternative medicines (CAMs) such as dietary supplements.

The discovery of eggshell membrane as a natural source of combined glucosamine, chondroitin, and hyaluronic acid has prompted the evaluation of this material as a potential treatment for OA. ESM Technologies, LLC (Carthage, MO) has developed methods to efficiently and effectively separate eggshell membrane from eggshells to create a shell-free eggshell membrane. The isolated membrane is then partially hydrolyzed using a proprietary process and dry-blended to produce 100% pure Natural Eggshell Membrane (NEM®).

In preliminary open-label human clinical trials totaling 37 subjects with OA, oral supplementation with 500 mg per day of NEM® resulted in an observed decrease in pain in 7-30 days. Therefore, an eight week randomized, multicenter, double blind, placebo controlled supplementation trial was conducted to evaluate the efficacy and safety of NEM® for the relief of the pain and stiffness associated with moderate OA of the knee - the Osteoarthritis Pain Treatment IncorpOrating NEM® (OPTION) trial.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • known symptomatic osteoarthritis of the knee
  • patients must have been diagnosed with functional Grades I-III of osteoarthritis according to the modified criteria of the American College of Rheumatology
  • must also have had persistent knee pain associated with osteoarthritis with a baseline score of at least 30 mm on the Patient's Assessment of Arthritis Pain - Visual Analog Scale
  • required to suspend all current pain relief medications. Subjects that were currently taking analgesic medications were eligible to participate in the study following a 14 day washout period for NSAIDs, a 7 day washout for narcotics, and a 90 day washout for injected steroids. Subjects currently taking glucosamine, chondroitin sulfate or MSM were only eligible after a 3-month washout period.

Exclusion Criteria:

  • are currently receiving remission-inducing drugs such as methotrexate or immunosuppressive medications or had received them within the past 3 months
  • had a confounding inflammatory disease or condition (rheumatoid arthritis, gout, pseudo gout, Paget's disease, chronic pain syndrome, etc.) that would interfere with assessment of pain associated with the index knee
  • body weight 250 pounds or greater
  • having a known allergy to eggs or egg products
  • pregnant or breastfeeding women
  • Subjects previously enrolled in a study to evaluate pain relief within the past 6 months or currently involved in any other research study involving an investigational product (drug, device, or biologic) or a new application of an approved product, within 30 days of screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00750477

Locations
United States, Missouri
Regional Specialty Clinic
Cuba, Missouri, United States, 65453
Regional Specialty Clinic
Kirksville, Missouri, United States, 63501
St. John's Clinic
Springfield, Missouri, United States, 65807
Sponsors and Collaborators
ESM Technologies, LLC
Investigators
Principal Investigator: Anne Winkler, MD, PhD St. John's Clinic - Rheumatology
Principal Investigator: Robert W Jackson, DO Regional Specialty Clinic
Study Director: Kevin J Ruff, PhD, MBA ESM Technologies, LLC
  More Information

Additional Information:
Publications:
Responsible Party: Kevin J. Ruff, Ph.D., MBA -- Director of Scientific & Regulatory Affiars, ESM Technologies, LLC
ClinicalTrials.gov Identifier: NCT00750477     History of Changes
Other Study ID Numbers: CLN # C0504
Study First Received: September 8, 2008
Last Updated: April 24, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by ESM Technologies, LLC:
osteoarthritis
arthritis
knee
eggshell
membrane
OPTION

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on August 19, 2014